Impact of adjuvant trastuzumab treatment on fatigue, emotional status and quality of personal and work life of patients with localised breast cancer: results of the 'HER-ception' study.
Anxiety
Breast cancer
Fatigue
HER2
Occupational health
Occupational reintegration
Quality of life
Return to work
Trastuzumab
Work life
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
16 Dec 2022
16 Dec 2022
Historique:
received:
01
08
2022
accepted:
11
11
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
21
12
2022
Statut:
epublish
Résumé
The aim of this study was to analyse the impact of adjuvant trastuzumab on fatigue, emotional status, and quality of personal and work life of patients treated for localised breast cancer. In a prospective setting, we recruited age-matched localised breast cancer patients, treated by adjuvant chemotherapy with (group 1) or without IV trastuzumab (group 2), between September 2011 and May 2014. Patients completed questionnaires on quality of life (FACT-G, FACT-B), fatigue (FACIT-F, ICQ), anxiety-depression (HADS), and work life (dedicated self-questionnaire) at inclusion then at 3, 6, 9, and 15 months. We included 35 patients in each group. No significant difference was found between the two groups concerning return to work, fatigue, and quality of life scores at each phase of the study. In total, 39 patients (72.2%) reported having returned to work at T15, with no significant difference between the two groups (p = 0.53). Significantly higher scores for'helplessness' outcomes were observed in group 1, 9, and 15 months (6.138 and 5.731; p = 0.047 and 0.048, respectively). Patients in group 1 reported higher score of anxiety-depression than group 2 at 3 months (p = 0.027) then no significant difference was observed at the other times of the study. Trastuzumab does not appear to affect fatigue and return to work in patients with localised breast cancer. The emotional well-being could be affected in patients treated by trastuzumab, with a more pronounced 'helplessness' feeling which could be more related to the additional follow-up imposed by the prescription of trastuzumab.
Identifiants
pubmed: 36525099
doi: 10.1007/s00520-022-07512-6
pii: 10.1007/s00520-022-07512-6
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
38Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30(8):1194–1220
doi: 10.1093/annonc/mdz173
Saad ED, Squifflet P, Burzykowski T, Quinaux E, Delaloge S, Mavroudis D et al (2019) Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol 20(3):361–370
doi: 10.1016/S1470-2045(18)30750-2
Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the herceptin adjuvant (HERA) trial. Lancet Lond Engl 389(10075):1195–1205
doi: 10.1016/S0140-6736(16)32616-2
Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol 24(9):2278–2284
doi: 10.1093/annonc/mdt182
Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M et al (2018) Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol Off J Eur Soc Med Oncol 29(3):646–653
doi: 10.1093/annonc/mdx773
Bower JE, Wiley J, Petersen L, Irwin M, Cole SW, Ganz PA (2018) Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories. Health Psychol Off J Div Health Psychol Am Psychol Assoc 37(11):1025–1034
Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, Di Meglio A, Pinto S et al (2020) Impact of breast cancer treatment on employment: results of a multicenter prospective cohort study (CANTO). J Clin Oncol 38(7):734–743
doi: 10.1200/JCO.19.01726
Joly F, Lange M, Dos Santos M, Vaz-Luis I, Di Meglio A (2019) Long-term fatigue and cognitive disorders in breast cancer survivors. Cancers 11(12):1896
doi: 10.3390/cancers11121896
Mokhtari-Hessari P, Montazeri A (2020) Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018. Health Qual Life Outcomes 18:338
doi: 10.1186/s12955-020-01591-x
Lueboonthavatchai P (2007) Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thail Chotmaihet Thangphaet 90(10):2164–2174
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655
doi: 10.1097/00000421-198212000-00014
Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52(2):69–77
doi: 10.1016/S0022-3999(01)00296-3
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E (1997) Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manag 13(2):63–74
doi: 10.1016/S0885-3924(96)00274-6
Nguyen J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D et al (2015) EORTC QLQ-BR23 and FACT-B for the assessment of quality of life in patients with breast cancer: a literature review. J Comp Eff Res 4(2):157–166
doi: 10.2217/cer.14.76
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol Off J Am Soc Clin Oncol 11(3):570–579
doi: 10.1200/JCO.1993.11.3.570
Hahn EA, Segawa E, Kaiser K, Cella D, Smith BD (2015) Validation of the functional assessment of cancer therapy-breast (FACT-B) quality of life instrument. J Clin Oncol 33(15_suppl):e17753–e17753
doi: 10.1200/jco.2015.33.15_suppl.e17753
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR et al (1997) Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol Off J Am Soc Clin Oncol 15(3):974–986
doi: 10.1200/JCO.1997.15.3.974
Evers AW, Kraaimaat FW, van Lankveld W, Jongen PJ, Jacobs JW, Bijlsma JW (2001) Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases. J Consult Clin Psychol 69(6):1026–1036
doi: 10.1037/0022-006X.69.6.1026
Wang XS, Woodruff JF (2015) Cancer-related and treatment-related fatigue. Gynecol Oncol 136(3):446–452
doi: 10.1016/j.ygyno.2014.10.013
Kowalczyk L, Deutschmann C, Crevenna R, Konrad S, Singer CF, Farr A (2021) Radiotherapy-induced fatigue in breast cancer patients. Breast Care 16(3):236–242
doi: 10.1159/000509410
Mohandas H, Jaganathan SK, Mani M, Ayyar M, Rohini Thevi GV (2017) Cancer-related fatigue treatment : an overview. J Cancer Res Ther 13(6):916929
Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139–144
doi: 10.1200/JCO.1998.16.1.139
de Boer AGEM, Taskila T, Ojajärvi A, van Dijk FJH, Verbeek JHAM (2009) Cancer survivors and unemployment: a meta-analysis and meta-regression. JAMA 301(7):753–762
doi: 10.1001/jama.2009.187
Endicott J, Nee J (1997) Endicott work productivity scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 33(1):13–16
Lerner D, Amick BC, Lee J, Rooney T, Rogers WH, Chang H, Berndt ER (2003) Relationship of employee-reported work limitations to work productivity. Med Care 41(5):649–659
doi: 10.1097/01.MLR.0000062551.76504.A9
Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis H, AH, (2010) Validity of the work productivity and activity impairment questionnaire - general health version in patients with rheumatoid arthritis. Arthritis Res Ther 12(5):R177
doi: 10.1186/ar3141
La vie cinq ans après un diagnostic de cancer - Rapport - Ref : ETUDVIEK518 [Internet]. [cited 2022 Jul 4]. Available from: https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/La-vie-cinq-ans-apres-un-diagnostic-de-cancer-Rapport
Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D et al (2010) NCCN clinical practice guidelines cancer-related fatigue. J Natl Compr Cancer Netw JNCCN 8(8):904–931
doi: 10.6004/jnccn.2010.0067
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141
doi: 10.1056/NEJMoa1406281
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L et al (2019) Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol 37(22):1868–1875
doi: 10.1200/JCO.19.00066
von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131
doi: 10.1056/NEJMoa1703643